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Abstract
Introduction Tumor invasion and metastasis remain a major
cause of mortality in breast cancer patients. High
concentrations of nitric oxide (NO) suppress tumor invasion and
metastasis in vivo. NO prodrugs generate large amounts of NO
upon metabolism by appropriate intracellular enzymes, and
therefore could have potential in the prevention and therapy of
metastatic breast cancer.
Methods The present study was designed to determine the
effects of the NO-releasing prodrug O2-(2,4-dinitrophenyl) 1-
[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-
K) on breast cancer invasion and the mechanisms involved.
MDA-MB-231, MDA-MB-231/F10, and MCF-7/COX-2 were
the three breast cancer cell lines tested. NO levels were
determined spectrophotometrically using a NO assay kit.
Invasion and the expression of matrix metalloproteinases
(MMPs) and tissue inhibitor of MMPs were determined using
Matrigel invasion assays, an MMP array kit and ELISAs. The
activity and expression of extracellular signal-regulated kinase 1/
2, p38, and c-Jun N-terminal kinase mitogen-activated protein
kinases were determined using western blot analyses.
Results Under conditions by which JS-K was not cytotoxic, JS-
K significantly decreased (P < 0.05) the invasiveness of breast
cancer cells across the Matrigel basement membrane, which
was directly correlated with NO production. JS-43-126, a non-
NO-releasing analog of JS-K, had no effect on NO levels or
invasion. JS-K increased (P  < 0.05) TIMP-2 production, and
blocking TIMP-2 activity with a neutralizing antibody significantly
increased (P < 0.05) the invasive activity of JS-K-treated cells
across Matrigel. JS-K decreased p38 activity, whereas the
activity and the expression of extracellular signal-regulated
kinase 1/2 and c-Jun N-terminal kinase were unaffected.
Conclusion We report the novel findings that JS-K inhibits
breast cancer invasion across the Matrigel basement
membrane, and NO production is vital for this activity.
Upregulation of TIMP-2 production is one mechanism by which
JS-K mediates its anti-invasive effects. JS-K and other NO
prodrugs may represent an innovative biological approach in the
prevention and treatment of metastatic breast cancer.
Introduction
Breast cancer is the most common cancer detected in
women, accounting for nearly one out of every three cancers
diagnosed in the United States. Metastasis is the primary
cause of breast cancer mortality. The 5-year survival rate for
women diagnosed with localized breast cancer is 98%, which
contrasts dramatically with the 27% survival rate of women
diagnosed with distant metastasis breast cancer [1] (data
based on the November 2006 SEER data submission, posted
to the SEER Okay web site in 2007. Development of effective
chemopreventive and therapeutic strategies for metastatic dis-
ease is urgently needed.
COX-2 = cyclooxygenase-2; DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-linked immunosorbent assay; ERK1/2 = extracellular 
signal-regulated kinase 1/2; FBS = fetal bovine serum; GST = glutathione S-transferase; JNK = c-Jun N-terminal kinase; JS-K = O2-(2,4-dinitrophenyl) 
1- [(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate; MMP = matrix metalloproteinase; MTS = 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NO = nitric oxide; NOS = nitric oxide synthase; TIMP = tissue inhibitor of matrix metalloproteinase.Breast Cancer Research    Vol 10 No 3    Simeone et al.
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The free radical nitric oxide (NO) plays an important role in reg-
ulating tumor growth and metastasis. The amount of NO pro-
duced depends on the expression of nitric oxide synthase
(NOS) isoforms. NOSI and NOSIII are expressed constitu-
tively and produce trace amounts of NO. NOSII is the induci-
ble isoform and can generate large amounts of NO.
Low concentrations of NOSIII-derived NO promoted the
growth, invasion, and metastasis of murine mammary tumors
[2,3]. In contrast, high levels of NOSII-mediated NO have
been shown to suppress tumorigenesis and metastasis in vivo
[4-8]. EMT-6J murine breast carcinoma cells, which constitu-
tively expressed inducible NOSII and secreted high levels of
NO, had a lower metastatic potential than NOSII-deficient
EMT-6H cells when injected into mice [6]. EMT-6H cells
induced the formation of numerous metastases in the lungs of
all the injected mice, while the number of mice with lung
metastases and the number of metastases per lung were
lower in the EMT-6J group [6]. Similarly, pancreatic cells trans-
duced with wild-type NOSII suppressed tumor growth and
distant metastasis to the liver in an orthotopic xenograft model
[8].
We previously demonstrated that breast cancer cells possess
intrinsic resistance mechanisms that can prevent the induction
of NOSII [9,10]; any chemopreventive or therapeutic strategy
designed to produce high NO levels in such cells should
therefore not depend on NOSII induction. Given the suppres-
sive effects of high levels of NO on tumorigenesis and metas-
tasis, drugs that supply NO exogenously could have potential
in breast cancer therapy and chemoprevention. The challenge
is to deliver NO in a sustained and controlled manner.
NO donors that spontaneously generate large amounts of NO
independent of NOSII induction are activated at physiological
pH and can induce NO-mediated systemic hypotension. NO
prodrugs are another type of NOSII-independent NO-releas-
ing agent. NO prodrugs do not release NO spontaneously, but
rather can be activated to generate high concentrations of NO
upon metabolism by intracellular enzyme targets. Arylated dia-
zeniumdiolates have been designed to be activated for NO
release by reaction with glutathione S-transferases (GSTs).
GSTs are a superfamily of enzymes that detoxify xenobiotics
by conjugating them to glutathione and increasing their cellular
excretion. Among the major isoforms (α,  μ,  π), GST-π is
expressed at the highest concentration in breast tumors
[11,12]. The expression of GST-π is associated with more
aggressive tumors, poor prognosis, increased risk of relapse,
and decreased disease-free survival in breast cancer patients
[13,14].
O2-(2,4-dinitrophenyl) 1- [(4-ethoxycarbonyl)piperazin-1-
yl]diazen-1-ium-1,2-diolate (JS-K), a diazeniumdiolate acti-
vated to release high levels of NO by GST enzymes [15], has
been shown to inhibit cancer cell growth in vitro and in vivo
[15-19]. Whether JS-K can suppress cancer invasion, how-
ever, is not known. In the present article we report the novel
findings that JS-K inhibits the invasive activity of breast cancer
cells across the Matrigel basement membrane at doses by
which JS-K was not cytotoxic, and that increasing TIMP-2 pro-
duction is one mechanism by which JS-K mediates its anti-
invasive effects. The results presented here have a bearing on
the potential for NO prodrugs to be used in the prevention and
therapy of metastatic breast cancer.
Materials and methods
Reagents
Matrigel and type I collagen were purchased from BD Bio-
sciences (Bedford, MA, USA) and Sigma-Aldrich Chemical
Co (St. Louis, MO, USA), respectively. Hema-3 was pur-
chased from Fisher Scientific (Middleton, VA, USA). Rabbit
polyclonal GST-π and GST-α antibodies were purchased from
EMD Biosciences (La Jolla, CA, USA). β-actin monoclonal
antibody was purchased from Sigma-Aldrich Chemical Co.
The polyclonal antibody to TIMP-2 was purchased from R & D
Systems (Minneapolis, MN, USA). Phospho(Thr202/Tyr204)-
extracellular signal-regulated kinase 1/2 (ERK1/2), ERK1/2,
phospho(Thr180/Tyr182)-p38, p38, phospho(Thr183/Tyr185)-c-
Jun N-terminal kinase (JNK), and JNK antibodies were pur-
chased from Cell Signaling (Beverly, MA, USA).
JS-K [20] and JS-43-126 [21], a JS-K analog that does not
release NO, were prepared as previously described. Stock
solutions of JS-K and JS-43-126 were prepared in dimethylsul-
foxide and were stored at -20°C. The structures of JS-K and
JS-43-126 are presented in Figure 1.
Figure 1
Structures of JS-K and JS-43-126, a non-nitric oxide-releasing JS-K  analog Structures of JS-K and JS-43-126, a non-nitric oxide-releasing JS-K 
analog.Available online http://breast-cancer-research.com/content/10/3/R44
Page 3 of 10
(page number not for citation purposes)
Cell lines and culture conditions
The human MDA-MB-231 breast cancer cell line was obtained
from American Type Cell Culture (Manassas, VA, USA). The
MDA-MB-231 cell line is an estrogen-independent, highly met-
astatic human breast cancer cell line. Breast cancer commonly
metastasizes to the skeletal system. MDA-MB-231/F10 (F10)
is a bone metastatic derivative of MDA-MB-231 cells selected
in vivo by repeated intracardiac injections of the MDA-MB-
231 cells into female nude mice until no micrometastases
were detected histologically in any organs other than bone
[22]. The F10 cell line was kindly provided by Dr Toshiyuki
Yoneda (The University of Texas Health Science Center, San
Antonio, TX, USA).
Breast cancer also commonly metastasizes to lymph nodes.
Elevated COX-2 expression in invasive breast tumor is associ-
ated with lymph node metastasis [23-25]. MCF-7/COX-2
cells are estrogen-dependent MCF-7 cells stably transfected
with plasmids encoding the human COX-2 gene [26]. The
parental MCF-7 cells are poorly invasive but the MCF-7/COX-
2 cells are highly invasive [27].
The MDA-MB-231 and F10 cell lines were cultured in DMEM/
F12 (Invitrogen, Carlsbad, CA, USA) supplemented with 5%
heat-inactivated FBS) (Invitrogen) at 37°C under 5% carbon
dioxide in a humidified incubator. MCF-7/COX-2 cells were
continuously cultured in DMEM/F12 medium containing 5%
FBS and 500 μg/ml antibiotic G418 (Invitrogen).
Western blot analysis
Protein lysates (50 μg) from untreated exponentially growing
MDA-MB-231, F10, and MCF-7/COX-2 breast cancer cells
were loaded onto 15% polyacrylamide gels to determine the
expression of GST-π and GST-α. The MDA-MB-231 cells (3
× 105 cells), F10 cells (3 × 105 cells), and MCF-7/COX-2 cells
(4 × 105 cells) were plated in T25 flasks in 5 ml DMEM/F12
medium supplemented with 5% FBS. The next day, cells were
treated with JS-K (0.5 and 1.0 μM) for 24 hours. Protein
lysates (30 μg) were loaded onto 12% polyacrylamide gels to
determine the activity and expression of ERK1/2, p38, and
JNK mitogen-activated protein kinases. Proteins were electro-
phoresed and electrotransferred as described previously [10].
Membranes were incubated with the appropriate antibodies.
β-actin was used as a loading control. Protein bands were vis-
ualized by enhanced chemiluminescence (Kirkgaard & Perry
Laboratories, Gaithersburg, MD, USA). Images were scanned
and quantified by an Alpha Innotech densitometer using the
Alpha Imager application program (San Leandro, CA, USA).
Nitric oxide assay
The MDA-MB-231 cells (3 × 105 cells), F10 cells (3 × 105
cells), and MCF-7/COX-2 cells (4 × 105 cells) were plated in
T25 flasks in 5 ml DMEM/F12 medium supplemented with 5%
FBS. The next day, cells were treated with JS-K (0.5 and 1.0
μM) or JS-43-126 (0.5 and 1.0 μM) for 72 hours. The medium
was recovered, centrifuged for 5 minutes, and concentrated
using spin columns with 10-kDa-cutoff filters (Millipore, Bed-
ford, MA, USA). Total NO was determined in the conditioned
concentrated supernatants by quantifying nitrite, the stable
end product of NO oxidation, spectrophotometrically using a
colorimetric nonenzymatic nitric oxide assay kit (Oxford Bio-
medical Research, Oxford, MI, USA) as described previously
[9]. Cell growth was determined by total live cell counts using
trypan blue exclusion. Nitrite values were normalized for total
cell counts and expressed as picomoles per 106 cells. The
experiments were performed in triplicate wells.
Proliferation assay
One hundred microliters of Matrigel (0.7 mg/ml) were added
to each well of 96-well plates. The MDA-MB-231 cells, F10
cells, and MCF/COX-2 cells (1 × 104 cells resuspended in
100 μl medium) were added to Matrigel-coated wells. The next
day, JS-K (0, 0.5 and 1.0 μM) was added to cells in pentapli-
cate wells. After 3 days of incubation, cell proliferation was
determined by the Promega (Madison, WI, USA) Celltiter 96®
AQueous nonradioactive cell proliferation assay. The CellTiter
96® AQueous Assay is composed of 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium (MTS) and the electron coupling reagent phenazine meth-
osulfate. MTS is reduced by live cells into a formazan product,
whose absorbance can be read at 490 nm. The quantity of for-
mazan product is directly proportional to the number of living
cells in culture. The absorbance of the formazan product was
read within 2 hours after the MTS/phenazine methosulfate dye
addition. Cell proliferation was expressed as the percentage of
untreated cells. The experiments were repeated twice.
Invasion assay
The effect of JS-K on breast cancer invasion was determined
in vitro using modified Boyden chamber assays as previously
described [28]. Briefly, six-well plate transwell inserts with 8-
μm pore-size polycarbonate filters (Fisher Scientific) were
coated with Matrigel (0.7 mg/ml) or type I collagen (20 μg/ml)
in cold serum-free DMEM/F12 medium and were placed at
room temperature for 40 minutes. Cells were trypsinized,
resuspended in serum-supplemented media, and were then
counted.
Cells were then washed three times with serum-free medium.
The MDA-MB-231 cells (3 × 105 cells), F10 cells (3 × 105
cells), and MCF-7/COX-2 cells (4 × 105 cells), resuspended
in 500 μl, were added into the Matrigel-coated or the collagen-
coated transwell inserts and were incubated for 72 hours in
the absence or presence of JS-K (0.5 and 1.0 μM) or JS-43-
126 (0.5 and 1.0 μM). The lower chambers were filled with 2
ml DMEM/F12 medium supplemented with 5% FBS. After
incubation, noninvading cells on the upper surface of the filter
were removed with cotton swabs. Cells that had invaded
through the pores onto the lower side of the filter were fixed,
stained with Hema-3, and photographed. The invaded cellsBreast Cancer Research    Vol 10 No 3    Simeone et al.
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were counted in five fields for each filter under a light micro-
scope at 40× magnification. The invasiveness of the cells was
expressed as the mean number of cells that had invaded to the
lower side of the filter. The experiments were performed in trip-
licate wells and were repeated twice.
To determine the importance of TIMP-2 in JS-K-mediated anti-
invasive effects, TIMP-2 activity was blocked with a neutraliz-
ing antibody (R & D Systems). The MDA-MB-231, F10, and
MCF-7/COX-2 cells were treated with 1 μM JS-K in the pres-
ence or absence of the anti-TIMP-2 antibody (2.5 μg/ml) for
72 hours in a Matrigel invasion assay. The experiments were
performed in triplicate wells and were repeated twice.
Collection of conditioned medium supernatant
The MDA-MB-231 cells (3 × 105 cells), F10 cells (3 × 105
cells), and MCF-7/COX-2 cells (4 × 105 cells) were plated in
T25 flasks in 5 ml DMEM/F12 medium supplemented with 5%
FBS. The next day, cells were treated with JS-K (0.5 and 1.0
μM) or JS-43-126 (0.5 and 1.0 μM) for 24 hours. The medium
in each flask was then replaced with serum-free medium and
the flasks were incubated for an additional 24 hours. The
medium was recovered, centrifuged for 5 minutes, and con-
centrated using spin columns with 10-kDa-cutoff filters. The
medium collected was used for the matrix metalloproteinase
(MMP) array and to determine the expression of TIMP-2.
Human matrix metalloproteinase array
The expression of MMPs and TIMPs in the conditioned
medium supernatant was qualitatively screened using a human
MMP array kit (RayBiotech, Norcross, GA, USA). The array
allows for the simultaneous detection of seven MMPs (MMP-
1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10, MMP-13) and
three TIMPs (TIMP-1, TIMP-2, TIMP-4). Images were scanned
using an Alpha Imager application program.
Enzyme-linked immunosorbent assays for TIMP-2
The concentration of TIMP-2 in the conditioned medium
supernatant was determined using a TIMP-2 ELISA kit (EMD
Biosciences). The concentration of TIMP-2 was normalized to
the cell number and was expressed as nanograms per milliliter
per 106 cells. The experiments were performed in triplicate
wells and were repeated three times.
Statistical analyses
For statistical analysis of the invasion experiments, the Sha-
piro-Wilk test was first performed to assess the normality of
assumption data. Given that the data were normally distrib-
uted, two-sample t tests were performed for each of the three
cell lines to compare the number of invading cells for the
untreated group with the number of invading cells for each
dose of JS-K and JS-43-126. The number of invading cells
was also compared between the two doses of JS-K and JS-
43-126. Two-sample t tests were also used to compare the
number of invading cells for the group treated with JS-K with
the number of invading cells for the group treated with JS-K in
the presence of the anti-TIMP-2 antibody for each cell line.
The significance level for each individual comparison (0.05/3
= 0.0167) was adjusted by the Bonferroni method to account
for multiple testing within each cell line to achieve an overall
significance level of 5%. All analyses were performed using
SAS software (SAS Institute, Inc., Cary, NC, USA). The same
statistical analyses were used to compare the NO and TIMP-
2 levels of untreated cells with those treated with JS-K or JS-
43-126 as appropriate.
Results
Expression of GST-π and GST-α in breast cancer cell 
lines
JS-K is activated to release NO by GST enzymes [15]; the
expression of GST-π and GST-α in MDA-MB-231, F10, and
MCF-7/COX-2 breast cancer cells was therefore determined.
The MDA-MB-231 and F10 cells expressed GST-π and GST-
α, but GST-π was the predominant isoform (Figure 2). MCF-7/
COX-2 cells expressed GST-α but not GST-π (Figure 2).
JS-K, but not JS-43-126, increases nitric oxide levels in 
breast cancer cells
NO levels were determined in untreated and JS-K-treated
MDA-MB-231, F10, and MCF-7/COX-2 cells to confirm drug
activation. The NO production was significantly increased (P
< 0.05) in the three cell lines as a result of JS-K treatment (Fig-
ure 3).
The NO levels were 2.1-fold and fourfold higher (P < 0.05) in
MDA-MB-231 cells treated with 0.5 and 1 μM JS-K, respec-
tively (Figure 3). The NO levels were increased (P < 0.05) 5.8-
fold and 6.1-fold at the 0.5 and 1 μM concentrations of JS-K
in F10 cells, respectively (Figure 3). Although the two
concentrations of JS-K did not differ (P > 0.05) in the NO lev-
els produced, the NO levels of JS-K-treated F10 cells were
Figure 2
Expression of glutathione S-transferase π and α isoforms in breast can- cer cell lines Expression of glutathione S-transferase π and α isoforms in breast can-
cer cell lines. Expression of glutathione S-transferase (GST)-π and 
GST-α isoforms in breast cancer cell lines. Protein lysates were 
obtained from exponentially growing MDA-MB-231, F10, and MCF-7/
COX-2 cells. Western blot analyses using polyclonal GST-π and GST-
α antibodies were performed. β-actin was used as a loading control.Available online http://breast-cancer-research.com/content/10/3/R44
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significantly higher (P < 0.05) in comparison with untreated
cells (Figure 3). The NO levels were increased (P < 0.05) 4.9-
fold and sevenfold in MCF-7/COX-2 cells at the 0.5 and 1 μM
concentrations of JS-K, respectively (Figure 3). JS-K can
therefore be activated to release NO by breast cancer cells. In
contrast, NO production was not different (P > 0.05) between
untreated cells and those treated with JS-43-126 for each of
the three cell lines (Figure 3).
JS-K, but not JS-43-126, decreases breast cancer 
invasion across a Matrigel-coated membrane
The invasion of cancer cells through basement membranes is
an essential step in cancer metastasis. Matrigel is a solubilized
basement membrane preparation extracted from the Engel-
breth-Holm-Swarm mouse sarcoma, a tumor rich in extracellu-
lar matrix proteins. The major component of Matrigel is laminin.
Matrigel has been used by numerous groups to assay the
invasive activity of tumor cells across the basement membrane
[29-31].
Matrigel invasion assays were performed to determine the
effect of JS-K on the invasiveness of breast cancer cells
across the basement membrane. Untreated MDA-MB-231,
F10, and MCF-7/COX-2 cells displayed a high invasive
capacity on Matrigel (Figure 4a). In all cell lines, JS-K signifi-
cantly (P < 0.05) reduced the number of invasive cells (Figure
4a, b). The number of invaded MDA-MB-231 cells was
decreased (P < 0.05) 37% and 85% at the 0.5 and 1 μM
doses of JS-K, respectively (Figure 4b). The number of
invaded F10 cells was reduced (P < 0.05) 63% and 76% by
the 0.5 and 1 μM doses of JS-K, respectively (Figure 4b). The
two doses of JS-K, however, did not have significantly different
(P > 0.05) anti-invasive effects in F10 cells (Figure 4b). In
MCF-7/COX-2 cells, JS-K reduced (P < 0.05) the number of
invaded cells 49% and 75% at the 0.5 and 1 μM doses of JS-
K, respectively (Figure 4b). In contrast, the invasiveness of the
three cell lines was unaffected by treatment with JS-43-126
(Figure 4b). JS-K can therefore decrease breast cancer inva-
sion across Matrigel, and this is dependent on NO production.
JS-K has been shown to induce growth inhibition in cancer
cells [15-19]. We determined the effects of JS-K on the prolif-
eration of breast cancer cells grown on Matrigel, in order to
mimic the conditions used in the Matrigel invasion assays. The
0.5 and 1.0 μM doses of JS-K induced < 20% growth inhibi-
tion in any of the breast cancer cell lines (Figure 4c). JS-K-
mediated decreases in the Matrigel invasion assays were
therefore not the result of growth inhibition.
Bone is the most prevalent site of first distant relapse of breast
cancer, with as many as 85% of patients with advanced breast
cancer suffering from bone metastases [32]. Type I collagen is
the most abundant protein within the bone, making up > 90%
of the total protein within this site [33]. Type I collagen has
been used to assay the invasive activity of tumor cells across
the bone matrix [34,35]. A type I collagen invasion assay was
performed to determine whether JS-K may inhibit the invasive-
ness of breast cancer cells across the bone matrix. The condi-
tions for the collagen invasion assay were identical to those of
the Matrigel invasion assay, except that type I collagen was
used to coat the transwell insert. The MDA-MB-231 and F10
cells displayed a high invasive capacity on type I collagen (Fig-
ure 4d), but MCF-7/COX-2 cells did not (data not shown). JS-
K did not reduce the invasiveness of breast cancer cells
across type I collagen-coated insert (Figure 4d). These data
indicate that JS-K can block breast cancer cells from invading
through Matrigel but not through type I collagen, suggesting
that JS-K can block breast cancer invasion through the base-
ment membrane but not through the bone matrix.
JS-K increases TIMP-2 production to block breast cancer 
cells from invading through Matrigel
MMPs, which are involved in the degradation of the basement
membrane, are essential to the invasive process. In contrast,
TIMPs regulate the activity of MMPs and protect the basement
membrane from proteolysis. A human MMP array was per-
formed to screen the effects of JS-K on MMP and TIMP pro-
duction. The array profiles for JS-43-126-treated cells were
similar to those of untreated cells (Figure 5a). In contrast, the
most consistent effect observed in the arrays of the three cell
lines as a result of JS-K treatment was an increase in the pro-
duction of TIMP-2 (Figure 5a). To confirm the JS-K-mediated
increase in TIMP-2 levels that were observed in the MMP
arrays, TIMP-2 ELISAs were performed. In MDA-MB-231
cells, TIMP-2 levels were increased (P < 0.05) 1.9-fold and
threefold at the 0.5 and 1 μM doses of JS-K, respectively,
while TIMP-2 was increased (P < 0.05) 1.5-fold and 7.2-fold
in F10 cells at the same doses (Figure 5b). In MCF-7/COX-2
cells, TIMP-2 was increased (P < 0.05) only at the higher dose
Figure 3
JS-K, but not JS-43-126, increases nitric oxide production in breast  cancer cells JS-K, but not JS-43-126, increases nitric oxide production in breast 
cancer cells. Conditioned medium supernatant was collected from 
MDA-MB-231, F10, and MCF-7/COX-2 cells treated in the absence or 
presence of JS-K or JS-43-126 for 72 hours. Total nitric oxide (NO) 
was determined by quantifying nitrite, the stable end product of NO oxi-
dation, spectrophotometrically using a colorimetric nonenzymatic nitric 
oxide assay kit. Nitrite values were normalized for total cell counts and 
expressed as picomoles per 106 cells. Columns indicate the mean of 
triplicate wells ± standard deviation. *Significant increase in NO levels 
relative to untreated cells, P < 0.05.Breast Cancer Research    Vol 10 No 3    Simeone et al.
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of JS-K (Figure 5b). TIMP-2 was increased (P < 0.05) twofold
in MCF-7/COX-2 cells at the 1 μM concentration of JS-K (Fig-
ure 5b). These data indicate that TIMP-2 may be the major, but
not the only, target of JS-K.
Next we determined the importance of TIMP-2 in the anti-inva-
sive effects of JS-K. To do this, TIMP-2 activity was blocked
with a commercially available neutralizing antibody and the
effect of JS-K on the invasiveness of MDA-MB-231, F10, and
MCF-7/COX-2 cells across Matrigel was determined. At the
concentration used, the anti-TIMP-2 antibody had no effect on
invasion (Figure 5c, d). JS-K decreased the invasiveness of all
cell lines across Matrigel; however, blocking TIMP-2 activity
significantly (P < 0.05) suppressed the anti-invasive effects of
JS-K (Figure 5c, d). In comparison with untreated MDA-MB-
231 cells, JS-K decreased (P < 0.05) the number of invaded
cells by 72% and 37% in the absence and presence of the
anti-TIMP-2 antibody, respectively (Figure 5d). The number of
invaded F10 cells was 72% and 40% lower (P < 0.05) relative
to untreated cells when treated with JS-K alone or in combina-
tion with the anti-TIMP-2 antibody, respectively (Figure 5d).
JS-K decreased (P < 0.05) the number of invaded MCF-7/
COX-2 cells by 65%, but in the presence of anti-TIMP-2 the
number of invaded cells was decreased (P < 0.05) by 30%
(Figure 5d). These data indicate that TIMP-2 is an important
mediator of the anti-invasive activity of JS-K across the
Matrigel basement membrane.
JS-K decreases p38 activity in breast cancer cells
Mitogen-activated protein kinase pathways, which have been
shown to regulate TIMP-2 [36-38], are activated by JS-K
[16,17]. We therefore determined whether these pathways
were involved in JS-K-mediated TIMP-2 production. In all cell
lines, p38 phosphorylation (indicative of activity) was unaf-
fected by the 0.5 μM concentration of JS-K (Figure 6). The 1.0
μM concentration of JS-K decreased p38 phosphorylation by
Figure 4
JS-K, but not JS-43-126, decreases the invasiveness of breast cancer cells across Matrigel JS-K, but not JS-43-126, decreases the invasiveness of breast cancer cells across Matrigel. (a) MDA-MB-231, F10, and MCF-7/COX-2 cells were 
added into Matrigel-coated transwell inserts and incubated with JS-K or JS-43-126 for 72 hours. Cells that invaded through the pores onto the lower 
side of the filter were fixed, stained, and photographed. (b) The number of invaded cells for each filter was counted in five fields. The invasiveness of 
the cells is expressed as the mean number of cells that invaded to the lower side of the filter. Columns indicate the mean of triplicate wells ± stand-
ard deviation. *Significant decrease in the number of invaded cells relative to untreated cells, P < 0.05. (c) MDA-MB-231, F10, and MCF-7/COX-2 
cells were plated on Matrigel-coated wells and incubated with JS-K. After 72 hours, cell proliferation was determined by Celltiter 96® AQueous nonra-
dioactive cell proliferation assay. Columns indicate the mean of pentaplicate wells ± standard deviation. (d) MDA-MB-231 and F10 cells were 
added into type I collagen-coated transwell inserts and incubated with JS-K for 72 hours. Cells that invaded through the pores onto the lower side of 
the filter were fixed, stained, and photographed.Available online http://breast-cancer-research.com/content/10/3/R44
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approximately 27%, 62%, and 70% in MDA-MB-231 cells,
F10 cells, and MCF-7/COX-2 cells, respectively (Figure 6). At
0.5 and 1.0 μM concentration, JS-K decreased ERK1/2 phos-
phorylation in F10 cells by 36% and 57%, respectively (Figure
6). In contrast, JS-K did not affect ERK1/2 phosphorylation in
MDA-MB-231 cells or MCF-7/COX-2 cells (Figure 6). The
phosphorylation of JNK was not affected by JS-K in any cell
line (Figure 6).
Discussion
JS-K is a NO prodrug that releases high levels of NO upon
conjugation with glutathione by GST enzymes [15]. JS-K has
been shown to inhibit the growth of cancer cells in vitro and in
vivo [15-19]. In addition to its growth inhibitory properties, JS-
K induces differentiation in leukemia cells [15] and possesses
anti-angiogenic activity in vitro [16]. In the present study, we
have identified inhibition of breast cancer invasion across the
Matrigel basement membrane as another important anticancer
activity of JS-K.
Cell invasion involves MMP-mediated proteolysis of the base-
ment membrane, which is counterbalanced by TIMPs. NO
donors have been shown to increase and decrease MMP
activity, depending on the cell type. NO donor-treated
rheumatoid synovial cells increased MMP-2 production, but
did not influence the production of TIMP-1 and TIMP-2 [39]. In
human fibrosarcoma cells and lung epithelial cancer cells, NO
donors inhibited MMP-2 secretion [40].
In the present study, JS-K increased TIMP-2 levels in breast
cancer cells. TIMP-2 has been shown to inhibit the invasive-
ness of breast cancer cells in vitro and in vivo. Overexpression
of TIMP-2 decreased the in vitro invasion of ras-transformed
breast epithelial cells [41]. Mice injected with TIMP-2-trans-
Figure 5
JS-K increases TIMP-2 production to suppress breast cancer invasion through Matrigel JS-K increases TIMP-2 production to suppress breast cancer invasion through Matrigel. (a) Expression of matrix metalloproteinases (MMPs) and tis-
sue inhibitor of matrix metalloproteinases (TIMPs) in the conditioned medium supernatant obtained from untreated and JS-K-treated cells was quali-
tatively screened using a human MMP array kit. (b) TIMP-2 levels in the conditioned medium supernatant obtained from untreated and JS-K-treated 
cells were determined using a commercial ELISA kit. Columns indicate the mean of triplicate wells ± standard deviation. *Significant increase in the 
TIMP-2 levels relative to untreated cells, P < 0.05. (c) MDA-MB-231, F10, and MCF-7/COX-2 cells were treated with JS-K (1 μM) in the presence 
or absence of a TIMP-2 neutralizing antibody (2.5 μg/ml) for 72 hours in a Matrigel invasion assay. (d) The number of invaded cells was counted. 
Columns indicate the mean of triplicate wells ± standard deviation. *Significant decrease in the number of invaded cells relative to untreated cells, P 
< 0.05. †Increase relative to JS-K-treated cells, P < 0.05.Breast Cancer Research    Vol 10 No 3    Simeone et al.
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fected MDA-MB-231 breast cancer cells had a lower number
of osteolytic bone metastases and a higher survival rate than
mice injected with nontransfected cells [42]. Liposome-com-
plexed  TIMP2  DNA constructs administered to MMTVneu
transgenic mice reduced tumor growth and effectively inhib-
ited the occurrence of lung metastases [43]. Our present find-
ings are consistent with these of TIMP-2 acting as a
suppressor of cell invasion. On the other hand, high levels of
TIMP-2 have also been correlated with distant metastasis of
breast tumors [44,45]. Our data indicate that TIMP-2 is an
important mediator of the anti-invasive activity of JS-K. Since
inhibition of TIMP-2 did not fully block the anti-invasive effects
of JS-K, however, other mechanisms are likely to be involved in
the anti-invasive effects of JS-K.
In the present study, JS-K was found to consistently decrease
the activity of p38, but not that of ERK1/2 or JNK, in breast
cancer cells. p38 has been shown to regulate TIMP-2 expres-
sion [37,38]. Downregulation of p38 activity increased TIMP-
2 production in squamous cell carcinoma [38]. Phorbol myr-
istate acetate-induced downregulation of TIMP-2 secretion
was reversed by inhibition of p38 in glioblastoma cells [36].
p38 activity was decreased only at the higher concentration of
JS-K, however, despite the fact that JS-K inhibited the invasive-
ness of breast cell lines across Matrigel in a dose-dependent
manner. p38 is not likely to be the major pathway involved in
the anti-invasive activity of JS-K.
Conclusion
Our results reveal a novel and important function for the NO-
releasing prodrug JS-K in suppressing the invasiveness of
breast cancer cells across the Matrigel basement membrane.
One mechanism by which JS-K inhibits breast cancer cell inva-
sion is the upregulation of TIMP-2 production. The invasion of
cancer cells through basement membrane is an essential step
in cancer metastasis. The ability of JS-K to suppress this
important step in the metastatic process indicates its potential
clinical relevance in the chemoprevention and therapy of met-
astatic breast cancer.
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